Alembic Pharma shares hit 20% upper circuit after 81% YoY rise in Q2 PAT
Indian markets moved higher in a quarterly results development.
· Business Standard Mkts
Alembic Pharma's revenue from operations increased by 36 per cent YoY to ₹2,603 crore during the said period from ₹1,910 crore a year ago.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- Sectors in the story: Pharma & Healthcare.
Pharma & Healthcare
1M +2.6% · 3M +1.0%
Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Zydus Lifesciences Q2 results: Net profit falls 26.6% to ₹925.5 crore
Lupin Q2 results: Net profit falls 22% to ₹1,155 cr, revenue at ₹7,827 cr
Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun Pharma
Q2 Results Live: Pfizer's One-Time Gain Lifts Profit; SBI Asset Quality Improves; Solar Industries Profit Zooms 79%
Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 crore